Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Product Pipeline Updates
Published on August 14, 2025
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, yesterday announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. Net loss for the second quarter of 2025 was $7.4 million compared with a net loss of $7.8 million for the same period in 2024. License and collaboration revenue totaled $2.9 million for the second quarter of 2025, compared with $1.1 million in the same period in 2024, the company reported.